Chimerix price target raised to $7 from $5 at JonesResearch

JonesResearch raised the firm’s price target on Chimerix (CMRX) to $7 from $5 and keeps a Buy rating on the shares. Chimerix provided additional color on the recent announcement for dordaviprone new drug application submission plan in recurrent H3K27M-mutated diffuse glioma setting, with management saying the NDA package is nearly complete, with plans to submit in the next few weeks, the analyst tells investors in a research note. Now that the focus is on the U.S. submission, the company will halt Australian approval efforts, noting they will provide further guidance when their plans mature, Jones adds.